toxylact: a06ag10 docusate sodium including combinations

The first professional lActological database in the word

Drugs in ATC class A06AG10 (docusate sodium, including combinations) are stool softener laxatives with minimal systemic absorption and are considered compatible with breastfeeding when used in standard doses and for short durations.medpedia.framar+3

Pharmacological group and composition

ATC class A06AG10 belongs to the subgroup A06AG “Enemas” within A06 “Drugs for constipation”.atcddd.fhi+1
The group comprises rectal preparations containing docusate sodium as the principal active substance, alone or in fixed combinations with other laxatives (e.g. stimulant or osmotic agents). These products are used to facilitate defecation in patients with constipation or difficult stool passage.mayoclinic+2

Mechanism of action and clinical use

Docusate sodium is a synthetic surfactant classified as a faecal softener that reduces surface tension at the interface between intestinal contents and mucosa.pdf.hres+1
It promotes water and electrolyte penetration into the stool, leading to hydration and softening of faecal masses and easier evacuation without significant stimulation of peristalsis.medpedia.framar+1
Preparations in class A06AG10 are indicated for short‑term relief of constipation and in situations where straining should be avoided, such as postpartum patients, after anorectal surgery or in painful defecation.pdf.hres+1

General toxicological profile

Docusate sodium administered orally or rectally is poorly absorbed from the gastrointestinal tract, resulting in very low systemic exposure in adults.ncbi.nlm.nih+2
At recommended doses, clinically relevant systemic toxicity is uncommon; reported adverse effects are mainly gastrointestinal, including abdominal pain, cramps and diarrhoea, with potential dehydration and electrolyte disturbance in severe cases.mayoclinic+2
Hypersensitivity reactions (e.g. rash) have been described rarely; toxic effects are more likely when docusate is combined with stimulant laxatives or used in excessive doses.drugs+2

Lactation toxicology

Available data indicate that docusate sodium is minimally absorbed and is unlikely to reach breast milk in more than trace amounts.ncbi.nlm.nih+2
LactMed and MotherToBaby state that measurable levels in maternal serum or milk are unlikely, and therefore clinically significant exposure of the breastfed infant is not expected when docusate is used at usual therapeutic doses.ncbi.nlm.nih+1
In one older postpartum trial using a combination of docusate with dantron, one breastfeeding mother reported infant diarrhoea, but the reaction was attributed to dantron rather than docusate.drugs
Major clinical guidelines and drug information sources regard docusate as acceptable during breastfeeding, usually recommending use for the shortest effective duration and favouring completely unabsorbed laxatives when possible.nhs+3

Risk assessment in breastfeeding

Given the pharmacokinetic characteristics and available clinical experience, docusate sodium in A06AG10 preparations is considered low risk for healthy term breastfed infants when used in standard doses.ncbi.nlm.nih+2
The theoretical risk of infant exposure is minimal; however, mothers should be counselled to monitor the infant for changes in stool consistency, feeding or behaviour, especially when using combination products containing stimulant components.breastfeedingnetwork+2
In cases of premature infants, infants with gastrointestinal disease, or prolonged maternal high‑dose use, individual risk–benefit assessment is advisable, and alternative non‑absorbed laxatives may be preferred.sps+1

Practical recommendations

For breastfeeding women, non‑pharmacological measures (dietary fibre, fluids, physical activity) remain first‑line management of constipation, with docusate used when these are insufficient.mayoclinic+1
When stool softening is specifically required and brief therapy is anticipated, A06AG10 docusate preparations can be used, avoiding unnecessary prolonged courses and high doses.nhs+3
Combination products that include stimulant laxatives should be reserved for selected cases and used with caution because of the higher likelihood of diarrhoea and electrolyte imbalance in the mother and potential indirect effects on the infant.sps+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.